Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2011

View Archived Issues

Johnson & Johnson recaps highlights of third quarter 2011

German research team presents new cyclin-dependent kinase 9 inhibitors

Ligand Pharmaceuticals and Sage Therapeutics enter licensing agreement

Analysis of TIRASMUS data identifies possible marker of temsirolimus efficacy in colorectal cancer

FDA accepts Lymphoseek NDA for review

Further phase I data reported on GDC-941 in metastatic and advanced cancer

New antibacterials show activity against Gram-positive and -negative pathogens

GlaxoSmithKline discloses new RIP-2 inhibitors

New agents for viral infections prepared by Vertex

Novel angiogenesis-promoting peptides patented in Korea

Dosing complete in phase II trial of oral PTH analogue in women with osteoporosis

Amicus closes recruitment in phase III Amigal study

Kinagen claims new protein kinase inhibitors

Promising 96-week data reported from phase II ocrelizumab trial in RRMS

FDA extends PDUFA date for Tysabri sBLA

Findings disclosed from ATON study evaluating atacicept in optic neuritis

Evotec and Apeiron Biologics collaborate on new target

Thrombogenics' ocriplasmin MAA accepted for review

Novel nitroxyl-releasing agents synthesized in U.S.

Isotechnika gives update on Luveniq strategy in Europe

Merck Serono to return full rights to Parkinson's disease candidate to Newron

OncoGenex Pharmaceuticals begins enrollment in OGX-427 study

Critical Outcome Technologies reports promising preclinical data on COTI-2

Protox Therapeutics' study of transrectal PRX-302 advances

EMA finds no link between cancer and use of angiotensin AT receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...